GlaxoSmithKline PLC ADR (GSK)vsMolson Coors Brewing Co Class B (TAP)
GSK
GlaxoSmithKline PLC ADR
$50.41
-0.18%
HEALTHCARE · Cap: $101.38B
TAP
Molson Coors Brewing Co Class B
$42.41
-1.67%
CONSUMER DEFENSIVE · Cap: $8.09B
Smart Verdict
WallStSmart Research — data-driven comparison
GlaxoSmithKline PLC ADR generates 193% more annual revenue ($32.78B vs $11.19B). GSK leads profitability with a 17.8% profit margin vs -18.9%. GSK appears more attractively valued with a PEG of 0.50. GSK earns a higher WallStSmart Score of 66/100 (B-).
GSK
Strong Buy66
out of 100
Grade: B-
TAP
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-3.1%
Fair Value
$56.71
Current Price
$50.41
$6.30 premium
Margin of Safety
+59.8%
Fair Value
$132.44
Current Price
$42.41
$90.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 36.3%
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Earnings expanding 35.6% YoY
Areas to Watch
1.5% revenue growth
Elevated debt levels
Distress zone — elevated risk
2.0% revenue growth
Expensive relative to growth rate
ROE of -18.1% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : TAP
The strongest argument for TAP centers on Price/Book, EPS Growth.
Bear Case : GSK
The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.
Bear Case : TAP
The primary concerns for TAP are Revenue Growth, PEG Ratio, Return on Equity.
Key Dynamics to Monitor
GSK profiles as a value stock while TAP is a turnaround play — different risk/reward profiles.
TAP carries more volatility with a beta of 0.44 — expect wider price swings.
TAP is growing revenue faster at 2.0% — sustainability is the question.
GSK generates stronger free cash flow (698M), providing more financial flexibility.
Bottom Line
GSK scores higher overall (66/100 vs 56/100), backed by strong 17.8% margins. TAP offers better value entry with a 59.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Molson Coors Brewing Co Class B
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
The Molson Coors Beverage Company, commonly known as Molson Coors, is a multinational drink and brewing company headquartered in Chicago in the United States.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?